Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05672030 · ClinicalTrials.gov registry record
Role of IL-5R Signaling in Non-eosinophil Upper Airway Cells in CRSwNP
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 30
- Enrollment target
NCT05672030 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 30 participants.
The verdict
NCT05672030 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
The overarching hypothesis of this proposal is that IL-5 acts on multiple sinus tissue cell types, including plasma cells and epithelial cells, to promote immune dysregulation, and that inhibition of IL-5 affects several relevant effector pathways that lead to clinical benefit.
Interventions
- OTHER Non-Interventional
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-10-01 |
| Est. Completion | 2023-12-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05672030
The ClinicalTrials.gov registry entry for NCT05672030 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Non-Interventional is the first listed.
NCT05672030 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05672030 about?
NCT05672030 is a clinical study titled "Role of IL-5R Signaling in Non-eosinophil Upper Airway Cells in CRSwNP". The overarching hypothesis of this proposal is that IL-5 acts on multiple sinus tissue cell types, including plasma cells and epithelial cells, to promote immune dysregulation, and that inhibition of IL-5 affects several relevant effector pathways that lead to clinical benefit.
What is the current status of trial NCT05672030?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2022-10-01. Estimated completion is 2023-12-01.
What interventions are being tested in trial NCT05672030?
The interventions under investigation include: Non-Interventional (OTHER).
Who is sponsoring clinical trial NCT05672030?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.